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Abstract 
A consistent feature of predictive testing guidelines for Huntington’s disease 
(HD) is the recommendation not to undertake predictive tests on those <18 
years. Exceptions are made but the extent of, and reasons for, deviation from 
the guidelines are unknown. The UK Huntington’s Prediction Consortium has 
collected data annually on predictive tests undertaken from the 23 UK genetic 
centres. DNA analysis for HD in the Netherlands is centralized in the Laboratory 
for Diagnostic Genome Analysis in Leiden.  In the UK, 60 tests were performed 
on minors between 1994 and 2015 representing 0.63% of the total number of 
tests performed. In the Netherlands, 23 tests were performed on minors 
between 1997 and 2016. The majority of the tests were performed on those 
aged 16 and 17 years for both countries (23% and 57% for the UK, and  26% 
and  57% for the Netherlands). Data on the reasons for testing were identified 
for 36 UK and 22 Netherlands cases and included: close to the age of 18 years, 
pregnancy, currently in local authority care and likely to have less support 
available after 18 years, person never having the capacity to consent and other 
miscellaneous reasons. 
This study documents the extent of HD testing of minors in the UK and the 
Netherlands and suggests that, in general, the recommendation is being 
followed. We provide some empirical evidence as to reasons why clinicians 
have departed from the recommendation. We do not advise changing the 
recommendation but suggest that testing of minors continues to be monitored.  
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Introduction  
Huntington’s disease (HD) is a well-known neurodegenerative disorder with age 
dependent penetrance (Walker 2007).  Predictive testing for HD became 
available in 1986 (Meissen et al 1988) and was initially undertaken as part of 
research projects; however, guidelines for predictive testing were developed 
and first published in 1989 and 1990 in neurology and genetics journals (World 
Federation of Neurology: Research Group on Huntington’s Chorea 1989, Went 
1990) and have since been updated twice (International Huntington Association 
and the World Federation of Neurology (WFN) Research Group on Huntington’s 
Chorea 1994a and 1994b, MacLeod et al 2013).  In the earlier versions the 
guidance was not to test before the age of majority but the latest update 
specifically states that “…the minimum age of testing be 18 years. Minors at risk 
requesting the test should have access to genetic counselling, support and 
information including discussion of all their options for dealing with being at 
risk.”  Elsewhere in that document there is a comment that the 
recommendations are “not intended as rigid rules but rather recommendations 
to guide and inform practice, based on current evidence and expertise” 
(MacLeod et al 2013).  The debate and recommendation not to test minors are 
based on theoretical concepts and long-standing clinical practice with limited 
empirical evidence available (Binedell et al 1996, Borry et al 2006, Duncan et al 
2007, Mand et al 2012, Clarke 2012, Mand et al 2013).  In this report we 
document the extent of predictive testing for minors in the UK and the 
Netherlands, and discuss some of the reasons why clinicians have departed 
from the guidelines/recommendations. 
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Methods 
Data Collection in the UK 
In the UK, a Huntington’s Prediction Consortium (UKHPC) was launched in 
1989 to collect annually anonymised data on predictive tests for HD performed 
in the UK. This database has been described previously and has been used to 
present data on the uptake of predictive testing in the UK (Baig et al 2016).  We 
analysed data from 1994 because that was the first full year for which predictive 
testing was available based on measurement of the CAG repeat length. Given 
the strong and consistent recommendation not to test those <18 years, the few 
cases where this had occurred were not included in that report.  We have now 
used the UKHPC database to report on the extent of predictive testing of minors 
in the UK.  Some reasons for predictive testing were noted on the database but, 
in addition, the UK clinical genetic centres were asked to give more detail on the 
reasons why a test was undertaken on a minor.  This request resulted in two 
additional cases being reported. 
 
Data Collection in the Netherlands 
DNA analysis for HD in the Netherlands is centralized in the Laboratory for 
Diagnostic Genome Analysis (LDGA), Department of Clinical Genetics, Leiden 
Medical University Center, Leiden, The Netherlands.  All requests for pre-
symptomatic testing of minors were identified from patients who had undergone 
DNA analysis for HD between January 1997 and December 2016.  The 
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referring clinical geneticists were asked to give more detail on the reasons for 
testing. 
Results 
There are 23 genetic centres in the UK but not all centres reported data for 
every year. In the period 1994-2015 there should have been 506 centre level 
annual reports (22 years x 23 centres) but in fact 476 (95%) were made.  
Testing of minors was reported from 20 of the 23 UK genetic centres.  There 
were 9,616 tests recorded on the database with 9,466 having an age of testing 
recorded.  63 tests were reported on patients <18 years but subsequently two 
entries were questioned and one entry was marked as already symptomatic.  
The extent of predictive testing of those <18 years in the UK is 60/9,463 = 
0.63%.  An equivalent figure was not available for the Netherlands data.  The 
male/female ratio for the UK data was 21:39. The ratio of normal to abnormal 
results was 38:22.  Neither ratio was significantly different from that seen in the 
UK adults having predictive tests (Baig et al 2016).  The prior probability was 
50% in 53 cases and 25% in 5 cases; in one case the prior probability was low 
because it was a re-test to confirm a previous pre-natal test result based on a 
linkage analysis; in a further case, the prior probability was difficult to determine 
from the UKHPC database.  
In the data from the Netherlands, the male/female ratio was 9:14; the ratio of 
normal to abnormal results was 5:18. The former ratio was the same as seen in 
a series of adults from the Netherlands having predictive tests from 2005-2011 
(102:141, unpublished data).  The latter ratio of normal:abnormal results was 
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significantly different from the data in adults: in a group of 107 individuals aged 
18-40 years having predictive tests the ratio was 55:52 Chi-square with Yates 
continuity correction = 5.56 (p-value = 0.018). The prior probability of minors 
being tested was 50% in 21 cases and 25% in one case.  In one case, the prior 
probability was low because of an intermediate allele in the mother. 
In the Netherlands series, not only were results skewed to abnormal, but in 
addition, half of expanded CAG repeat lengths were in the high range (48-56 
repeats), associated with younger age at onset.  Similar data are not available 
from the UK because the actual CAG repeat length was not recorded on the 
UKHPC database. 
Some comments on the reasons for testing were recorded on the database but 
centres were also contacted to provide more detail on the reasons for the 
predictive test.  This resulted in the description of two cases not recorded on the 
database.  Reasons for testing 36 cases from the UK and 22 from the 
Netherlands are summarised in Table 1.  The age structure of predictive tests 
undertaken on minors in the UK and the Netherlands is shown in Fig 1; it can be 
seen that that most tests of minors were performed on those aged 16 and 17 
years (23% and 57% respectively for the UK and 26% and 57% for the 
Netherlands). 
One of the additional cases reported from the UK was a boy with a maternal 
family history of HD and paternal family history of seizures.  He had an 
unremarkable birth history but developed neonatal seizures at 5 days.  By the 
age of 4 years he had evidence of developmental delay and intention tremor.  
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An MRI scan showed normal basal ganglia but a small cerebellum was 
questioned.  He had brisk lower limb reflexes and by the age of 5 years juvenile 
onset HD was considered.  He had a diagnostic test for HD and the result was 
normal.  
 
 
Discussion 
The current recommendation advising against predictive tests of minors (under 
18 years) for HD is based on theoretical concerns, long-standing clinical 
practice and expert opinion of experienced practitioners (MacLeod et al 2013).   
We have provided some empirical evidence for the extent of predictive testing 
of minors in the UK. In both the UK and the Netherlands, the most common 
reason for testing a minor was that the young person was close to 18 years and 
counselling sessions had been undertaken.  
Testing was also performed in a small number of cases in relation to a 
pregnancy. Discussion of options when a person at 50% risk of HD (or his 
partner) presents already pregnant is challenging; perhaps more so if the 
person is under 18 years. One issue for discussion is attitudes toward pre-natal 
testing and termination of pregnancy. If predictive testing is considered prior to 
pre-natal testing then the time-scale for the counselling process is reduced and 
this recognised as an exception in the current guidelines (MacLeod et al., 
2013). If the person is under 18 years then this departs from the guidelines in 
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two respects. There are other options for managing a pregnancy including 
exclusion testing or direct pre-natal testing in the full knowledge that there is a 1 
in 4 chance that the at-risk person and fetus have inherited the HD mutation. 
Difficulties can arise if individuals change their minds after a predictive test and 
decide not to have a pre-natal test, or if they decide not to go ahead with a 
termination of pregnancy after having a pre-natal test with an adverse result. 
However, these points are outside the scope of this paper. 
One small category of cases relates to a young person in foster care, or some 
other form of institutional care, when more support may be available to them as 
a minor rather than waiting until after 18 years when there might be less support 
available.  The counsellor has to be as confident as possible that the request is 
coming from the young person and that the implications for the future are 
understood. It has to be acknowledged that it is impossible to know if the young 
person would still request predictive testing after having left the “care” 
environment.  We also noted cases where the young person had another 
condition (Down syndrome or severe autism) which meant that the ability to 
consent was impaired, and was expected to remain so irrespective of the age of 
testing; therefore, the basis for the testing was an assessment of the best 
interests of the young person in terms of decisions to be made regarding 
planning for future care. In both cases the mother gave consent.  An unusual 
scenario which occurred more than once was that juvenile HD had occurred in 
the family and testing of a sibling was undertaken <18 years.  Each such case 
has to be assessed individually.   
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Another scenario which occurred more than once was that all siblings in a 
sibship requested to be tested pre-symptomatically at the same time, including 
one or two minors. Repeated attempts to exclude the minors from such “group 
based” testing were made but this led to strong feelings of isolation and not 
being part of the family dynamics.  For the sake of the family system, predictive 
testing was undertaken in those cases after a careful counselling procedure. 
Testing sibships in these circumstances is controversial and we would not want 
this to set a precedent.  
We have reported one diagnostic test performed because the possibility of 
juvenile HD was raised.  It was not reported to the database because it had 
been performed as a potentially diagnostic test but it illustrates that challenging 
scenarios occasionally arise in at-risk patients with neurological or behavioural 
problems.  Such a “diagnostic” test could be predictive, and difficult to interpret, 
if the CAG repeat expansion was not in the range clearly associated with 
juvenile onset disease. For this reason, there are recommendations that if a 
child has exclusively behavioural problems, cognitive (and imaging) studies 
should be performed and repeated to assess whether there has been decline in 
function (Nance 2009,Quarrell et al 2013). 
In several files from the Netherlands cases it was noted that the parent was 
young when he or she developed symptoms of HD and this may, in part, explain 
the reason for the higher CAG repeat lengths of the abnormal results. Given the 
early age of onset in their parent, offspring may feel a greater urge to know their 
own status at a younger age than offspring of a parent whose onset was in their 
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mid-forties or later.  They (or their caregivers) may also experience subtle 
changes in behaviour and executive functions at a younger age, and 
consequently question whether such changes represent the onset of symptoms 
at a younger age.  This was the case in two minors in the Netherlands series, 
who presented behavioural problems at the time of their request. 
In one case the testing procedure departed from the protocol as the request 
came from a paediatric neurologist.  The laboratory noticed this only after DNA 
analysis had been completed.  After consultation, the results were sent to a 
clinical geneticist, who reported the results in the first contact with the family.  In 
order to prevent recurrence of this difficult situation, the Netherlands laboratory 
now keeps strictly to the rule that pre-symptomatic testing can only be ordered 
by a clinical geneticist and the reason for testing is checked with the referring 
clinician for all requests regarding minors (including apparently diagnostic 
ones).  
 The relatively small number of tests which have been undertaken, and the fact 
that the majority were performed on those aged 17 years, suggests that the 
guideline is generally being observed. The current recommendation 
acknowledges that there was controversy surrounding the age cut-off at 18 
years with some authors opting for a less restrictive recommendation. It was 
deemed necessary in the absence of evidence of harms or benefits of testing 
minors (MacLeod et al 2013).  In these circumstances, one may always argue 
that a person aged 17.5 years may be as mature as someone aged 18 years. 
Some have argued that when a young person presents for a predictive test 
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there should be an assessment of the young person’s maturity (Binedell et al 
1996). Unless the recommendation is changed, testing at 17 years should still 
be considered an exception. It should be noted that both in the UK and the 
Netherlands a young person at age 16 years can be presumed to have the 
capacity to consent (General Medical Council 2007, Artikel 447 Wet 
Geneeskundige Behandelingsovereenkomst (WGBO) 1995).   A significant 
weakness of this study is that we have no information on the longer term 
outcomes of the testing.  Recording of cases by the UKHPC is voluntary, with a 
high reporting rate, but we cannot be sure that all cases in the UK are 
submitted.  This information was extracted from a large data set and the 
accompanying notes on the reasons for testing are frequently brief; there are no 
notes to indicate why the very young children were tested. Some of the reasons 
for testing a minor which have been reported here may be more controversial 
than others; for example, testing the sibling of a case of juvenile HD. The 
controversy being that the young person should be deciding for themselves but 
without more detail it is difficult to comment. 
In conclusion, we do not advocate that the guidelines are changed but rather 
that the practice of testing minors continues to be assessed carefully by genetic 
counsellors and clinical geneticists on a case by case basis.  The reasons for 
testing outside the recommendation should be documented carefully and we 
suggest that a decision to deviate from the recommendation is not left with a 
counsellor and/or a clinician but should, where possible, be discussed more 
widely with other professionals or in a multidisciplinary team . Wherever 
possible, counsellors and clinicians should follow up such cases to assess 
Testing Minors for Huntington’s Disease  
 
14 
 
whether harm has been done so that more empirical evidence may be 
gathered. The practice of laboratories accepting referrals for predictive tests 
and apparently diagnostic tests for HD on minors only in conjunction with 
clinical geneticists or genetic counsellors appears reasonable.  
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Titles and Legends to Figures 
Figure 1 
Age structure of 60 predictive tests undertaken in the UK 1994 – 2015 and 23 in the 
Netherlands 1997 -2016 
Light grey represents the UK predictive testing of minors 
Dark grey represents The Netherlands testing of minors 
 
Table I 
Summary of reasons for testing minors in the UK 1994-2015 and the Netherlands 1997-
2016 
